BOXED WARNING Increased mortality in elderly patients with dementia-related psychosis treated with antipsychotics; not approved for dementia-related psychosis.
FDA dosing
Population
Start
Target
Max
Schizophrenia (milder)
Adults
2 mg TID
15 mg/day
60 mg/day
Schizophrenia (more severe)
Adults
5 mg BID
20-30 mg/day
60 mg/day
Renal Undefined
Hepatic Undefined
Exceeding 60 mg/day rarely increases benefit
Instructions
Individualize dose; start small and increase gradually to optimal effect
Some patients maintained on once-daily dosing
Not recommended in children under 12 years
Contraindications
Circulatory collapse
Comatose states or CNS depression due to any cause
Blood dyscrasias
Cautions
Tardive dyskinesia with long-term use
Neuroleptic malignant syndrome (NMS)
Extrapyramidal symptoms and dystonia, especially early and at higher doses
Orthostatic hypotension/syncope (do not use epinephrine as pressor)